SequelSEC

Nuvectis Pharma, Inc. NVCT

Pharmaceutical Preparations · CIK 0001875558 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$27.57M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Nuvectis Pharma, Inc. (NVCT) reported net income of -$26.44M for the fiscal year ended 2025-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Nuvectis Pharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Nuvectis Pharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$27.57M-$19.85M-$22.90M-$19.23M-$12.89M
Net income-$26.44M-$19.00M-$22.26M-$19.08M-$12.89M
Research & development$18.15M$12.92M$15.38M$13.23M$9.54M
Weighted-average diluted sharesshares 21.81Mshares 17.11Mshares 15.56Mshares 12.66Mshares 4.27M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.32$-1.11$-1.43$-1.51$-3.02
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$9.42M$6.93M$7.52M$6.01M$3.35M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Nuvectis Pharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Cash & equivalents$31.63M$18.53M$19.13M$19.99M$5.74M
Total assets$31.71M$18.61M$19.18M$20.40M$6.66M
Current assets$31.71M$18.61M$19.18M$20.40M$5.83M
Total liabilities$13.30M$8.89M$6.98M$6.19M$2.42M
Current liabilities$13.30M$8.89M$6.98M$6.19M$2.42M
Total equity incl. NCI$18.41M$9.71M$12.20M$14.22M-$11.01M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$15.25M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$6.27M$2.50M$2.77M$2.91M$1.06M

Cash flow

Nuvectis Pharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Operating cash flow-$16.01M-$12.25M-$15.95M-$13.56M-$9.50M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailable$0$0$0Unavailable
Financing cash flow$29.11M$11.65M$15.09M$27.81M$15.25M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$6.03M$4.86M$4.70M$1.71M$1.89M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Nuvectis Pharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.38x2.09x2.75x3.30x2.41x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NVCT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.